Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.56 |
| ▸ | BACE1 | P56817 | 5/20 | 0.56 |
| ▸ | BCHE | P06276 | 4/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
| ▸ | SSTR5 | P35346 | 4/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | UBE2M | P61081 | 1/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110483 | 0.91 | ACHE (0.49) | ACHEBACE1BCHESIGMAR1SSTR5 | |
| SCHEMBL4108787 | 0.91 | NSD2 (0.49) | ACHEBACE1BCHESIGMAR1NSD2 | |
| SCHEMBL4116078 | 0.89 | ACHE (0.49) | ACHEBACE1BCHESIGMAR1NSD2 | |
| SCHEMBL4120483 | 0.88 | ACHE (0.47) | ACHEBACE1BCHESIGMAR1NSD2 | |
| SCHEMBL4110027 | 0.87 | ACHE (0.69) | ACHEBACE1BCHESIGMAR1MEN1 | |
| SCHEMBL4111210 | 0.87 | ACHE (0.46) | ACHEBACE1BCHESIGMAR1SSTR5 | |
| SCHEMBL4114243 | 0.87 | BACE1 (0.50) | ACHEBACE1BCHESIGMAR1NSD2 | |
| SCHEMBL7161609 | 0.86 | HCRTR1 (0.51) | ACHEBACE1BCHEPOLB | |
| SCHEMBL4764246 | 0.86 | BACE1 (0.51) | ACHEBACE1BCHESIGMAR1 | |
| SCHEMBL4127456 | 0.85 | ACHE (0.46) | ACHEBACE1BCHESIGMAR1NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20060040986-A1 | Erythropoietin production accelerator | KOWA CO., LTD. (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1568691-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | Kowa Co., Ltd. (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20050176764-A1 | Medicine for treating cancer | KOWA CO., LTD (JP) | 2005-08-11 | — | — | US | disclosed |
| US-6867221-B2 | Cyclic amine compounds and pharmaceutical composition containing the same | KOWA CO., LTD. (JP) | 2005-03-15 | — | — | US | disclosed |
| EP-1494670-A1 | MEDICINE FOR TREATING CANCER | Kowa Co., Ltd. (JP) | 2005-01-12 | — | — | EP | disclosed |
| EP-1422219-A1 | CYCLIC AMINE COMPOUND | Kowa Co., Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20040010147-A1 | Cyclic amine compounds and pharmaceutical composition containing the same | KOWA CO., LTD. (JP) | 2004-01-15 | — | — | US | disclosed |
| WO-2003086397-A1 | MEDICINE FOR TREATING CANCER | KOWA CO., LTD. (JP) | 2003-10-23 | — | — | WO | disclosed |
| US-6605620-B1 | Such as 4-(N-(4-Methoxyphenyl)-N-(3-(3,4,5-trimethoxy-phenyl)-benzoylamino)-1-((2 -(3,4,5-trimethoxyphenyl)pyridin-4-yl)-methyl)piperidine; treatment and prevention of cell adhesion or infiltration | KOWA CO., LTD. (JP) | 2003-08-12 | — | — | US | disclosed |
| US-6498169-B1 | CELL ADHESION AND INFILTRATION INHIBITORS; ANTIASTHMATICS, ANTIALLERGENS, ANTIRHEUMATICS, ANTIARTERIOSCLEROTICS, ANTIINFLAMMATORIES AND ANTI SJOGREN'S SYNDROME AGENTS | KOWA CO., LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176764-A1 | Medicine for treating cancer | HDAC4, HDAC3, NR4A3 | ACHE 4596/4885BACE1 4421/4885BCHE 4168/4885 |
| US-20060040986-A1 | Erythropoietin production accelerator | EPOR, GHRHR, ARL1 | ACHE 4797/4885BACE1 4563/4885BCHE 4545/4885 |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | EPOR, GHRHR, ARL1 | ACHE 4797/4885BACE1 4563/4885BCHE 4545/4885 |
| US-20040010147-A1 | Cyclic amine compounds and pharmaceutical composition containing the same | HRH3, HRH4, CNKSR1 | ACHE 2123/4885BACE1 2231/4885BCHE 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.